Join

Compare · NVS vs UPC

NVS vs UPC

Side-by-side comparison of Novartis AG (NVS) and Universe Pharmaceuticals Inc. (UPC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVS and UPC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $277.58B, about 150225.4x UPC ($1.8M).
  • Over the past year, NVS is up 29.1% and UPC is down 50.6% - NVS leads by 79.7 points.
  • UPC has hit the wire 1 time in the past 4 weeks while NVS has been quiet.
  • NVS has more recent analyst coverage (25 ratings vs 0 for UPC).
PerformanceNVS+29.12%UPC-50.60%
2025-04-28+0.00%2026-04-24
MetricNVSUPC
Company
Novartis AG
Universe Pharmaceuticals Inc.
Price
$145.43-1.37%
$2.89-0.69%
Market cap
$277.58B
$1.8M
1M return
-3.48%
+19.42%
1Y return
+29.12%
-50.60%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
0
1
Recent ratings
25
0
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

UPC

Universe Pharmaceuticals Inc.

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.